[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362258-105":59,"doc-detail-362258-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-monocytes-and-their-derivatives-in-ovarian-cancer-opportunities-for-innovation-in-prognosis-and-therapy","Targeting Monocytes and Their Derivatives in Ovarian Cancer - Opportunities for Innovation in Prognosis and Therapy","","Ovarian cancer remains the most lethal gynaecological malignancy due to late-stage diagnosis, frequent recurrence, and restricted treatment effectiveness. Existing diagnostic approaches, including imaging and serum biomarkers, provide insufficient sensitivity and specificity for early detection. Accumulating evidence emphasizes the pivotal role of myeloid-derived immune cells in the tumour microenvironment, where monocytes and their derivatives drive immune suppression, chemoresistance, and metastatic spread. Their recruitment and polarization involve multiple signalling pathways that may be therapeutically targeted, while monocyte depletion, TAM reprogramming, MDSC maturation, DC vaccines, and combination strategies are discussed. Accessible prognostic ratios, such as lymphocyte-to-monocyte ratio and monocyte-to-lymphocyte ratio, may forecast aggressiveness and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-monocytes-and-their-derivatives-in-ovarian-cancer-opportunities-for-innovation-in-prognosis-and-therapy/362258/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-monocytes-and-their-derivatives-in-ovarian-cancer-opportunities-for-innovation-in-prognosis-and-therapy/362258.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main focus of the review on monocytes in ovarian cancer?","Question",{"text":112,"@type":113},"The review examines how monocytes and their derivatives shape ovarian cancer progression, either by promoting tumour growth or contributing to anti-cancer immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are current ovarian cancer diagnostic tools limited for early detection?",{"text":117,"@type":113},"Imaging and serum markers lack sufficient sensitivity and specificity, making early detection difficult.",{"name":119,"@type":110,"acceptedAnswer":120},"Which therapeutic strategies are discussed to target monocytes and related myeloid cells?",{"text":121,"@type":113},"Strategies include monocyte depletion, reprogramming tumour-associated macrophages (TAMs), promoting MDSC maturation, dendritic cell (DC) vaccines, and combining these approaches with chemotherapy or immune checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362258,1790192791,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nTargeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy  \nDharvind Balan 1, Nirmala Chandralega Kampan 1, Mohamad Nasir Shafiee 1, Magdalena Plebanski 2 and Nor Haslinda Abd Aziz 1, *  \nAcademic Editor: Dawen Zhao  \nReceived: 6 November 2025  \nRevised: 11 December 2025  \nAccepted: 30 December 2025  \nPublished: 21 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Obstetrics and Gynaecology, Faculty of Medicine, National University of Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia; [dharvind1810@gmail.com](dharvind1810@gmail.com) (D.B.); [nirmala@ppukm.ukm.edu.my](nirmala@ppukm.ukm.edu.my) (N.C.K.); [nasirshafiee@ukm.edu.my](nasirshafiee@ukm.edu.my) (M.N.S.)  \n2 School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia; [magdalena.plebanski@rmit.edu.au](magdalena.plebanski@rmit.edu.au)  \n* [Correspondence: norhaslinda.abdaziz@ppukm.ukm.edu.my](Correspondence: norhaslinda.abdaziz@ppukm.ukm.edu.my)  \nSimple Summary  \nOvarian cancer is a serious disease that is often discovered at an advanced stage with limited treatment options and modest outcomes. This review explores the role of immune cells, mainly monocytes and their derivatives, which can either fight cancer or help it grow. This review also highlights how these cells contribute to ovarian cancer development and how they might be targeted to improve treatment outcomes. We also discuss the imbalance between different immune cells, and this may help predict the disease progression and patient outcomes. By understanding how monocytes and their related cells influence ovarian cancer, researchers and clinicians may be able to design better diagnostic tools and more effective personalised therapies in the future.  \nAbstract  \nOvarian cancer remains the most lethal gynaecological malignancy primarily due to latestage diagnosis, high recurrence rate, and limited treatment efficacy. Current diagnostic tools, including imaging and serum markers, lack sufficient sensitivity and specificity for early detection. Increasing evidence highlights the critical role of myeloid-derived immune cells within the tumour microenvironment in shaping ovarian cancer progression and therapy response. Monocytes and their derivatives are central regulators of immune suppression, chemoresistance, and metastatic dissemination in ovarian tumours. Their recruitment and polarisation are governed by several signalling pathways offering promising therapeutic targets. Strategies including monocyte depletion, TAM reprogramming, MDSC maturation, DC vaccines, and their synergistic use with chemotherapy or immune checkpoint inhibitors are being explored to restore anti-tumour immunity in ovarian cancer. Parallel to therapeutic potential, the lymphocyte-to-monocyte ratio and its reciprocal monocyte-to-lymphocyte ratio have also emerged as potential accessible and cost-effective prognostic tools that predict disease aggressiveness and survival in ovarian cancer. This review features the diagnostic, prognostic, and therapeutic significance of monocytes and their derivatives in ovarian cancer management and highlighting new opportunities for next-generation immunomodulatory therapies.  \nKeywords: ovarian cancer; monocytes; TAMs; DCs; MDSCs; LMR; MLR; prognostic biomarkers  \n1. Introduction  \nOvarian cancer is one of the most lethal gynaecological malignancies, frequently diagnosed at an advanced stage due to its non-specific early symptoms. Globally, more than 324,000 new cases and over 200,000 deaths are reported annually, with survival rates varying significantly by stage at diagnosis [1] . While patients with early-stage disease (stage I–II) may achieve 5-year survival rates of 70–95%, those with adva","cbCaijKd39Axib7x","https://ap.wps.com/l/cbCaijKd39Axib7x","pdf",1542275,35,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n## Immune components of the tumour microenvironment (TME)\n## Monocytes and their downstream derivatives in ovarian tumours","[{\"question\":\"What is the main focus of the review on monocytes in ovarian cancer?\",\"answer\":\"The review examines how monocytes and their derivatives shape ovarian cancer progression, either by promoting tumour growth or contributing to anti-cancer immune responses.\"},{\"question\":\"Why are current ovarian cancer diagnostic tools limited for early detection?\",\"answer\":\"Imaging and serum markers lack sufficient sensitivity and specificity, making early detection difficult.\"},{\"question\":\"Which therapeutic strategies are discussed to target monocytes and related myeloid cells?\",\"answer\":\"Strategies include monocyte depletion, reprogramming tumour-associated macrophages (TAMs), promoting MDSC maturation, dendritic cell (DC) vaccines, and combining these approaches with chemotherapy or immune checkpoint inhibitors.\"}]","Targeting Monocytes and Their Derivatives in Ovarian Cancer - Opportunities for Innovation in Prognosis and Therapy | PDF",1790146910,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/248bfef5ad6f0ae8a46d5c9b0bdf05f5.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ca54eb382e22d4a0dd531a55998bfb3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f0ff1b8e1fa8514d00108f50b5385c1.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2c1d16f3e27e6165d436d3dd6ab2ebb.webp",980,1385]